Trial Profile
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Iodine-131 (Primary) ; Vemurafenib (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- 14 Jun 2023 Planned End Date changed from 1 May 2023 to 1 May 2025.
- 14 Jun 2023 Planned primary completion date changed from 1 May 2023 to 1 May 2025.
- 25 Feb 2021 Planned End Date changed from 1 May 2021 to 1 May 2023.